Scancell Holdings (LSE:SCLP) Interest Expense : £-1.14 Mil (TTM As of Oct. 2023)

View and export this data going back to 2010. Start your Free Trial

What is Scancell Holdings Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Scancell Holdings's interest expense for the six months ended in Oct. 2023 was £ -0.49 Mil. Its interest expense for the trailing twelve months (TTM) ended in Oct. 2023 was £-1.14 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Scancell Holdings's Operating Income for the six months ended in Oct. 2023 was £ -8.12 Mil. Scancell Holdings's Interest Expense for the six months ended in Oct. 2023 was £ -0.49 Mil. Scancell Holdings did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Scancell Holdings Interest Expense Historical Data

The historical data trend for Scancell Holdings's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scancell Holdings Interest Expense Chart

Scancell Holdings Annual Data

Trend

Apr14

Apr15

Apr16

Apr17

Apr18

Apr19

Apr20

Apr21

Apr22

Apr23

Interest Expense

Get a 7-Day Free Trial

-1.65

-1.78

-1.22

Scancell Holdings Semi-Annual Data
	Apr14	Oct14	Apr15	Oct15	Apr16	Oct16	Apr17	Oct17	Apr18	Oct18	Apr19	Oct19	Apr20	Oct20	Apr21	Oct21	Apr22	Oct22	Apr23	Oct23
Interest Expense	Get a 7-Day Free Trial															-1.73	-0.05	-0.57	-0.65	-0.49

Scancell Holdings Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Oct. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was £-1.14 Mil.

Scancell Holdings (LSE:SCLP) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Scancell Holdings's Interest Expense for the six months ended in Oct. 2023 was £-0.49 Mil. Its Operating Income for the six months ended in Oct. 2023 was £-8.12 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Oct. 2023 was £19.51 Mil.

Scancell Holdings's Interest Coverage for the quarter that ended in Oct. 2023 is calculated as

Scancell Holdings did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Scancell Holdings (LSE:SCLP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scancell Holdings PLC (LSE:SCLP) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

SCLP.GB:UK SCP:Germany

Address

Sanders Road, Unit 202, Bellhouse Building, Oxford Science Park, Oxford, GBR, OX4 4GD

Website

https://www.scancell.co.uk

Scancell Holdings PLC is engaged in the discovery and development of novel vaccines for the treatment of cancer. The company is exploiting the unrivalled potential of the immune system to seek out and destroy cancer using two proprietary immuno-oncology platforms: ImmunoBody and Moditope. Its potent innovative DNA-based ImmunoBody therapies generate ultra-high avidity T cell responses that target and eliminate cancerous tumors. Its Moditope platform technology overcomes the immune suppression induced by tumors themselves, allowing activated T cells to seek out and kill tumor cells that would otherwise be hidden from the immune system.

Scancell Holdings (LSE:SCLP) Headlines

No Headlines